kabutan

StemRIM(4599) Summary

4599
TSE Growth
StemRIM
256
JPY
+1
(+0.39%)
Dec 5, 1:25 pm JST
1.65
USD
Dec 4, 11:25 pm EST
Result
PTS
outside of trading hours
256.2
Dec 5, 12:46 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.71
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
254 JPY 1.63 USD
Previous Close Dec 4
255 JPY 1.64 USD
High Dec 5, 10:06 am
257 JPY 1.65 USD
Low Dec 5, 9:00 am
254 JPY 1.63 USD
Volume
56,800
Trading Value
0.01B JPY 0.09M USD
VWAP
255.07 JPY 1.65 USD
Minimum Trading Value
25,600 JPY 165 USD
Market Cap
0.02T JPY 0.10B USD
Number of Trades
84
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
246
1-Year High Apr 4, 2025
1,107
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 2,652,000
Nov 21, 2025 0 2,652,200
Nov 14, 2025 0 2,684,400
Nov 7, 2025 0 2,710,700
Oct 31, 2025 0 2,685,700
Company Profile
StemRIM is a biotech venture originating from Osaka University, developing "regeneration-inducing medicine" that promotes self-tissue regeneration.
Sector
Pharmaceuticals
StemRIM is a research and development-based pharmaceutical venture founded at Osaka University. The company is engaged in the research and development of its proprietary "regeneration-inducing medicine" that promotes self-tissue regeneration and healing. This technology aims to achieve effects equivalent to regenerative medicine without using living cells, instead activating patients' own internal stem cells through compound administration to function broadly against various diseases. The company's lead pipeline product, redasemtide, is currently undergoing clinical trials for epidermolysis bullosa and acute cerebral infarction. Additionally, StemRIM is advancing research and development in a wide range of regeneration-inducing medical technologies, including novel peptides for systemic and local administration, therapeutic autologous cell collection devices, and stem cell gene therapy. Through these technologies, StemRIM aims to overcome the challenges of conventional regenerative medicine and realize safer and more effective treatment methods.